drugset / Trial / NCT06512883

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

NCT06512883

Phase 3 Recruiting 14 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.

Timeline

Start
2025-04-17
Primary completion
2028-02-20
Completion
2029-05-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Benralizumab Monoclonal antibody Subcutaneous